Cornell Research Foundation Inc.

Brown, Pinnisi & Michaels, Pc

Xinfang Ma

John G Babish

Brian E Johnson

Sakina El-Tom

Joseph A Rininger

Goeffrey Wheelock

Debra S Whiting

In vivo and in vitro assays for the detection and quantification of substances, which are carcinogenic, but not genotoxic or mutagenic, by measuring a correlative change in cyclin dependent kinases (CDK).

Assays for nongenotoxic, chemical carcinogens

This invention relates to the determination of in vivo exposure to dioxinlike compounds and the in vitro quantitation of dioxinlike compounds based on protein tyrosine phosphorylation as mediated by the Ah receptor. The extent of protein tyrosine phosphorylation is determined by monoclonal antibodies to protein tyrosine phosphate. The amount and nature of protein tyrosylphosphate is quantitatively related to the in vivo or in vitro concentration of dioxin to which animals or cells were exposed. This method permits detection of dioxinlike compounds at concentrations in the parts per trillion and parts per billion range.

Indirect immunoassay for dioxinlike compounds

Growing community of inventors

Ithaca, NY, United States of America

Xinfang Ma